Developing Breakthrough Medicines.
Improving Lives.

We are focused on developing programs
against targets with well-established biology

We are Experienced
Drug Developers

At Pimera, we have an experienced team with a successful track record in drug development and company building.  We have leveraged these skills to create a deep pipeline of programs advancing through the clinic with large market opportunities in cancer and other diseases with high unmet medical need.

Our Lead Program is PMR-116

PMR-116 is our lead therapeutic in clinical development for multiple cancer indications including solid tumors.  PMR-116 acts through a novel mechanism of action, targeting the RNA polymerase I, or POL I, a transcription factor for MYC driven cancers and other diseases with high unmet medical need.

We are Always Discovering.

We are also working on several discovery-stage efforts where we understand the underlying disease biology and believe that we can identify a novel therapeutic approach.

Featured News

Go to Top